- Home
- IPA
as 07-26-2024 4:00pm EST
ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from Europe.
| Founded: | 1983 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 29.5M | IPO Year: | 2017 |
| Target Price: | $7.00 | AVG Volume (30 days): | 58.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $2.73 | Next Earning Date: | 09-12-2024 |
| Revenue: | $17,671,642 | Revenue Growth: | 16.75% |
| Revenue Growth (this year): | 20.18% | Revenue Growth (next year): | 21.26% |
Latest ImmunoPrecise Antibodies Ltd. News
IPA Breaking Stock News: Dive into IPA Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
Business Wire
10 days ago
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
Business Wire
11 days ago
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
Business Wire
a month ago
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
Business Wire
a month ago
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
Business Wire
a month ago
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
Business Wire
2 months ago
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
Business Wire
2 months ago
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
Compare IPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPA ImmunoPrecise Antibodies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.